Active ingredient
- acalabrutinib
Legal Category
POM: Prescription only medicine
POM: Prescription only medicine
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.
Below is a text only representation of the Patient Information Leaflet. The original leaflet can be viewed using the link above.
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet are: EU/1/20/1479/001 , EU/1/20/1479/002.
Calquence 100 mg hard capsules (Northern Ireland)
Package leaflet: Information for the patient
Calquence 100 mg hard capsules
acalabrutinib
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
What is in this leaflet:
1. What Calquence is and what it is used for
2. What you need to know before you take Calquence
3. How to take Calquence
4. Possible side effects
5. How to store Calquence
6. Contents of the pack and other information
1. What Calquence is and what it is used for
What Calquence is
Calquence is a medicine used to treat cancer.
What Calquence is used for
Calquence is used to treat adults with chronic lymphocytic leukaemia (CLL).
CLL is a cancer of white blood cells called B-lymphocytes (or B-cells). These cells are part of the immune system (the body’s defences).
How Calquence works
Calquence works by blocking BTK, a protein in the body that helps these cancer cells grow and survive. By blocking BTK, Calquence helps to kill and can reduce the number of cancer cells which can slow down the worsening of the disease.
If you have any questions about how Calquence works or why this medicine has been prescribed for you, ask your doctor, pharmacist or nurse.
2. What you need to know before you take Calquence
Do not take Calquence if:
If you are not sure, talk to your doctor, pharmacist or nurse before taking Calquence.
Warnings and precautions
Talk to your doctor, pharmacist or nurse before taking Calquence if you:
Talk to your doctor if you develop a new lesion or any change in the appearance of an area on the skin as you are at a high risk of developing skin cancer, see section 4. Use sun protection and make regular skin examination.
Your doctor will check your blood cell counts as needed during treatment.
Children and adolescents
Do not give this medicine to children or adolescents aged less than 18 years. This is because it has not been studied in this age group.
Other medicines and Calquence
Tell your doctor, pharmacist or nurse if you are taking or have recently taken or might take any other medicines, especially if you take any of the following:
Medicines that increase your risk of bleeding
Calquence may make you bleed more easily. Tell your doctor, pharmacist, or nurse if you take other medicines that increase your risk of bleeding:
Pregnancy
Talk to your doctor before taking Calquence if you are pregnant, think you may be pregnant, or are planning on having a baby. This is because Calquence may harm your unborn baby.
Breast-feeding
Do not breast-feed during treatment with Calquence and for 2 days after your last dose of Calquence. It is not known if Calquence passes into your breast milk.
Driving and using machines
Calquence is unlikely to affect the ability to drive and use machines. However, if you feel dizzy, weak or tired while taking Calquence, you must not drive or use machines.
Calquence contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’.
3. How to take Calquence
Calquence will only be prescribed to you by a doctor with experience in the use of medicines for cancer. Always take Calquence exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.
How much to take
How to take
If you take more Calquence than you should
If you have taken more Calquence than you should, see a doctor or go to the nearest hospital straight away. Take the capsules and this leaflet with you.
If you forget to take a dose
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop taking Calquence and contact a doctor or go to your nearest emergency department immediately if you experience any of the following symptoms:
Common serious side effects (may affect up to 1 in 10 people)
Uncommon serious side effects (may affect up to 1 in 100 people)
Other side effects:
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Uncommon side effects (may affect up to 1 in 100 people)
Reporting of side effects
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via:
United Kingdom
or search for MHRA Yellow Card in the Google Play or Apple App Store.
By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Calquence
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister foil and carton after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What Calquence contains
The active substance is acalabrutinib. Each hard capsule contains 100 mg of acalabrutinib.
The other ingredients are:
What Calquence looks like and contents of the pack
Calquence is a hard gelatine capsule with a yellow body, blue cap, 20 mm hard capsule, marked with “ACA 100 mg” in black.
Calquence is supplied in aluminium blisters containing either 6 or 8 hard capsules. Each carton contains either 56 or 60 hard capsules.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Manufacturer
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
This leaflet was last revised in 11/2020
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu
ONC 20 0033
Horizon Place, 600 Capability Green, Luton, Bedfordshire, LU1 3LU
+44 (0)1582 838 000
+44 (0)1582 836 000
0800 783 0033
+44 (0)1582 838 003